10:01 ET -- Sanofi is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. Sanofi said a second phase 3 trial of Dupixent met its primary endpoint with what the company said was overwhelming efficacy. Sanofi said its Notus trial confirmed positive published results from the Phase 3 Boreas trial. The Notus trial found that the treatment "significantly reduced exacerbations," and that treatment with Dupixent led to rapid and significant improvements in lung function for patients with the life-threatening respiratory disease COPD. Dow Jones & Co. owns Factiva. (chris.wack@wsj.com)

 

(END) Dow Jones Newswires

November 27, 2023 10:16 ET (15:16 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024 Click aqui para mais gráficos Sanofi.
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024 Click aqui para mais gráficos Sanofi.